Stock AnalizHaemonetics Corp. HAE
Medical/Dental Instruments · IPO 1991 · data as of November 13, 2026
Haemonetics Corp. (HAE) is a healthcare company listed in the US with a market value of about $5.6B. In the twelve months to September 26, 2026 it had revenue of $1.4B and net income of $104M, a net margin of 7.5%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is shareholder returns (3/5); the weakest is value (1/5).
Key numbers: a P/E of 54.4, a price to free cash flow of 18.8, 5-year revenue growth of 9% a year, a 5-year average ROIC of 6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 37% below the current price.
Score: 1.8 / 5
Checks passed
- P/FCF below 20
- 3-year free cash flow growth above 10% a year
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- Positive free cash flow
- Interest covered more than 5 times
- Share count down over 3 years (buybacks)
- 20% to 100% of free cash flow returned to shareholders
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.3B | $1.4B | $1.3B | $1.2B | $993M | $870M | $988M | $968M | $904M | $886M |
| Net income | $104M | $97M | $168M | $118M | $115M | $43M | $79M | $77M | $55M | $46M | -$26M |
| Free cash flow | $298M | $260M | $142M | $144M | $82M | $76M | $72M | $109M | $40M | $146M | $84M |
| EPS (diluted) | $2.26 | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 | $1.55 | $1.48 | $1.04 | $0.85 | $-0.51 |
| Net margin | 7.5% | 7.3% | 12.3% | 9.0% | 9.9% | 4.4% | 9.1% | 7.7% | 5.7% | 5.0% | -3.0% |
| ROIC | — | 5.7% | 8.2% | 7.0% | 7.7% | 3.5% | 4.7% | 8.8% | 6.1% | 4.3% | -1.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $144.00, 17% above the current price; targets range from $115.00 to $165.00; the consensus rating is “Buy”; expected EPS is $5.33 for the fiscal year ending March 31, 2027.
Frequently asked questions
What is Haemonetics’s P/E ratio?
About 54.4, based on the last twelve months of diluted earnings per share (forward P/E about 20.6).
Is Haemonetics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 37% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Haemonetics pay a dividend?
Not currently.
Is Haemonetics a good stock to buy?
We do not give buy or sell advice. Haemonetics scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.